Sustained benefit from combined plasmapheresis and allogeneic mesenchymal stem cells transplantation therapy in systemic sclerosis

Table 1 Clinical and demographic characteristics of the patients enrolled in the study

Case	Age (years)	Sex	Duration (mo)	MRSS baseline	Organ involvement	Previous treatments	Maintain treatments	Infectious AE
1	26	M	17	26		P 15 mg/d + MTX 10 mg/w	P 5 mg/d + MTX 10 mg/w	Minor respiratory tract infection
2	21	F	24	23		P10mg/d + penicillamine 0.375/d	No treatment
3	25	M	6	19		no treatment	No treatment
4	35	F	30	17		P 5 mg/d + penicillamine 0.375/d	No treatment
5	28	F	84	21	ILD acral ulcers	P 20 mg/d + CTX 0.4/2 w	P 10 mg/d + CTX 0.6/2 mo	Minor respiratory tract infection
6	43	F	60	20		Penicillamine 0.375/d	No treatment
7	19	F	36	19		P 10 mg/d + AZA100 mg/d	P 5 mg/d + AZA50 mg/d	Minor respiratory tract infection
8	56	M	40	15	ILD	P 15 mg/d CTX 0.4/2 w	P 5 mg/d CTX 0.4/mo	Minor respiratory tract infection
9	46	F	7	21		P 10 mg/d + GTW	GTW
10	30	F	42	18		P10mg/d + MMF 0.75 BID	No treatment	Minor respiratory tract infection
11	38	F	12	20	ILD dysphagia	P 20 mg/d + CTX 0.1 QD + GTW	P10mg + CTX 0.4/2 w + GTW
12	67	F	6	25		P 10 mg/d + AZA 100 mg/d	P 5 mg/d + AZA 50 mg/d	Diarrhea
13	53	F	6	17		P 5 mg/d + MMF 0.75 BID	P 5 mg/d
14	36	F	6	21		No treatment	No treatment

Duration was from the first symptom of disease to the time receiving plasmapheresis (PE) + mesenchymal stem cell transplantation (MSCT). Skin MRSS modified Rodnan skin score, AE adverse events, ILD interstitial lung disease, P prednisone, CTX cyclophasphomide, MTX methotrexate, AZA azathioprine, GTW glycosides of Tripterygium wilfordi, MMF mycophenolate mofetil, BID twice daily

ISSN: 1478-6362